Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:
4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1
clinical trial in patients with relapsed or refractory systemic
light-chain (AL) amyloidosis did not meet the first of two primary
endpoints. Treatment with NINLARO^TM (ixazomib) in combination
with dexamethasone did not demonstrate a significant improvement in
overall hematologic response compared to physician’s choice of standard
of care regimens. As a result of this analysis, Takeda has decided to
discontinue the trial.

“While we are disappointed with this outcome, we aim to maximize our
learnings from this trial and share findings with the community in hopes
of helping to improve care for patients living with this devastating
disease,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area
Unit, Takeda. “This has been one of the largest studies ever conducted
in systemic light-chain AL amyloidosis and we are proud to have led it.
This study demonstrated our dedication to this rare and traditionally
difficult-to-enroll patient population and we thank the patients and
investigators for their engagement and participation. We remain
optimistic about NINLARO and continue to investigate NINLARO in patient
populations across the continuum of multiple myeloma care.”

An Independent Data Monitoring Committee (IDMC) did not raise any
concerns about the safety profile of NINLARO in this setting. Patients
are encouraged to consult their study investigators to address any
questions.

About the TOURMALINE-AL1 Trial

TOURMALINE-AL1 (NCT01659658) is an international, randomized,
controlled, open-label, multicenter, Phase 3 study, designed to
determine whether NINLARO^TM (ixazomib) in combination with
dexamethasone improves hematologic response, 2-year vital organ (heart
or kidney) deterioration and mortality rate versus a physician’s choice
of a chemotherapy regimen in participants diagnosed with relapsed or
refractory systemic light chain (AL) amyloidosis. Patients were randomly
selected to receive either NINLARO plus dexamethasone, or physician’s
choice of dexamethasone plus melphalan; dexamethasone plus
cyclophosphamide; dexamethasone plus thalidomide; dexamethasone plus
lenalidomide; or dexamethasone alone. For more information, please visit https://clinicaltrials.gov/ct2/show/NCT01659658.

About AL Amyloidosis

Primary AL amyloidosis is a condition that falls under the umbrella of
plasma cell dyscrasias. AL amyloidosis arises from a clonal plasma cell
that produces abnormal immunoglobulin light-chain fragments. These
misfolded light-chains form insoluble fibrils that aggregate as amyloid
deposits in organs and tissues throughout the body, ultimately leading
to organ dysfunction and death. The most common organs affected are the
kidneys, heart, liver, and autonomic or peripheral nerves. There are
currently no treatments approved for the treatment of AL amyloidosis.

About NINLARO™ (ixazomib) capsules

NINLARO™ (ixazomib) is an oral proteasome inhibitor which is being
studied across the continuum of multiple myeloma treatment settings.
NINLARO was first approved by the U.S. Food and Drug Administration
(FDA) in November 2015 and is indicated in combination with lenalidomide
and dexamethasone for the treatment of patients with multiple myeloma
who have received at least one prior therapy. NINLARO is currently
approved in more than 60 countries, including the United States, Japan
and in the European Union, with more than 10 regulatory filings
currently under review. It was the first oral proteasome inhibitor to
enter Phase 3 clinical trials and to receive approval.

The comprehensive ixazomib clinical development program, TOURMALINE,
includes four ongoing pivotal trials, which together are investigating
major multiple myeloma patient populations.

• TOURMALINE-MM1, investigating ixazomib vs. placebo in combination with
  lenalidomide and dexamethasone in relapsed and/or refractory multiple
  myeloma
• TOURMALINE-MM2, investigating ixazomib vs. placebo in combination with
  lenalidomide and dexamethasone in patients with newly diagnosed
  multiple myeloma
• TOURMALINE-MM3, investigating ixazomib vs. placebo as maintenance
  therapy in patients with newly diagnosed multiple myeloma following
  induction therapy and autologous stem cell transplant (ASCT)
• TOURMALINE-MM4, investigating ixazomib vs. placebo as maintenance
  therapy in patients with newly diagnosed multiple myeloma who have not
  undergone ASCT; this study is currently enrolling

In addition to the TOURMALINE program, ixazomib is being evaluated in
multiple therapeutic combinations for various patient populations in
investigator initiated studies globally.

NINLARO™ (ixazomib) capsules: Global
Important Safety Information

SPECIAL WARNINGS AND PRECAUTIONS
Thrombocytopenia has
been reported with NINLARO (28% vs. 14% in the NINLARO and placebo
regimens, respectively) with platelet nadirs typically occurring between
Days 14-21 of each 28-day cycle and recovery to baseline by the start of
the next cycle. It did not result in an increase in hemorrhagic events
or platelet transfusions. Monitor platelet counts at least monthly
during treatment with NINLARO and consider more frequent monitoring
during the first three cycles. Manage with dose modifications and
platelet transfusions as per standard medical guidelines.

Gastrointestinal toxicities have been reported in the NINLARO and
placebo regimens respectively, such as diarrhea (42% vs. 36%),
constipation (34% vs. 25%), nausea (26% vs. 21%), and vomiting (22% vs.
11%), occasionally requiring use of antiemetic and anti-diarrheal
medications, and supportive care.

Peripheral neuropathy was reported with NINLARO (28% vs. 21% in
the NINLARO and placebo regimens, respectively). The most commonly
reported reaction was peripheral sensory neuropathy (19% and 14% in the
NINLARO and placebo regimens, respectively). Peripheral motor neuropathy
was not commonly reported in either regimen (< 1%). Monitor patients for
symptoms of peripheral neuropathy and adjust dosing as needed.

Peripheral edema was reported with NINLARO (25% vs. 18% in the
NINLARO and placebo regimens, respectively). Evaluate patients for
underlying causes and provide supportive care, as necessary. Adjust the
dose of dexamethasone per its prescribing information or the dose of
NINLARO for severe symptoms.

Cutaneous reactions occurred in 19% of patients in the NINLARO
regimen compared to 11% of patients in the placebo regimen. The most
common type of rash reported in both regimens was maculo-papular and
macular rash. Manage rash with supportive care, dose modification or
discontinuation.

Hepatotoxicity, drug-induced liver injury, hepatocellular injury,
hepatic steatosis, and hepatitis cholestatic have been uncommonly
reported with NINLARO. Monitor hepatic enzymes regularly and adjust dose
for Grade 3 or 4 symptoms.

Pregnancy– NINLARO can cause fetal harm. Advise male and female
patients of reproductive potential to use contraceptive measures during
treatment and for an additional 90 days after the final dose of NINLARO.
Women of childbearing potential should avoid becoming pregnant while
taking NINLARO due to potential hazard to the fetus. Women using
hormonal contraceptives should use an additional barrier method of
contraception.

Lactation– It is not known whether NINLARO or its metabolites are
excreted in human milk. There could be potential adverse events in
nursing infants and therefore breastfeeding should be discontinued.

SPECIAL PATIENT POPULATIONS
Hepatic Impairment:
Reduce the NINLARO starting dose to 3 mg in patients with
moderate or severe hepatic impairment.

Renal Impairment: Reduce the NINLARO starting dose to 3 mg
in patients with severe renal impairment or end-stage renal disease
(ESRD) requiring dialysis. NINLARO is not dialyzable and, therefore, can
be administered without regard to the timing of dialysis.

DRUG INTERACTIONS
Co-administration of strong CYP3A inducers
with NINLARO is not recommended.

ADVERSE REACTIONS
The most frequently reported adverse
reactions (≥ 20%) in the NINLARO regimen, and greater than in the
placebo regimen, were diarrhea (42% vs. 36%), constipation (34% vs.
25%), thrombocytopenia (28% vs. 14%), peripheral neuropathy (28% vs.
21%), nausea (26% vs. 21%), peripheral edema (25% vs. 18%), vomiting
(22% vs. 11%), and back pain (21% vs. 16%). Serious adverse reactions
reported in ≥ 2% of patients included thrombocytopenia (2%) and diarrhea
(2%). For each adverse reaction, one or more of the three drugs was
discontinued in ≤ 1% of patients in the NINLARO regimen.

For European Union Summary of Product Characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/003844/WC500217620.pdf
For
US Prescribing Information: https://www.ninlarohcp.com/pdf/prescribing-information.pdf
For
Canada Product Monograph: http://www.takedacanada.com/ninlaropm

About Takeda Pharmaceutical Company
Takeda Pharmaceutical
Company Limited (TSE:4502/NYSE:TAK)
is a global, values-based, R&D-driven biopharmaceutical leader
headquartered in Japan, committed to bringing Better Health and a
Brighter Future to patients by translating science into
highly-innovative medicines. Takeda focuses its R&D efforts on four
therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and
Rare Diseases. We also make targeted R&D investments in Plasma-Derived
Therapies and Vaccines. We are focusing on developing highly innovative
medicines that contribute to making a difference in people’s lives by
advancing the frontier of new treatment options and leveraging our
enhanced collaborative R&D engine and capabilities to create a robust,
modality-diverse pipeline. Our employees are committed to improving
quality of life for patients and to working with our partners in health
care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

Important Notice
For the purposes of this notice, “press
release” means this document, any oral presentation, any question and
answer session and any written or oral material discussed or distributed
by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this
release. This press release (including any oral briefing and any
question-and-answer in connection with it) is not intended to, and does
not constitute, represent or form part of any offer, invitation or
solicitation of any offer to purchase, otherwise acquire, subscribe for,
exchange, sell or otherwise dispose of, any securities or the
solicitation of any vote or approval in any jurisdiction. No shares or
other securities are being offered to the public by means of this press
release. No offering of securities shall be made in the United States
except pursuant to registration under the U.S. Securities Act of 1933,
as amended, or an exemption therefrom. This press release is being given
(together with any further information which may be provided to the
recipient) on the condition that it is for use by the recipient for
information purposes only (and not for the evaluation of any investment,
acquisition, disposal or any other transaction). Any failure to comply
with these restrictions may constitute a violation of applicable
securities laws.

The companies in which Takeda directly and indirectly owns investments
are separate entities. In this press release, “Takeda” is sometimes used
for convenience where references are made to Takeda and its subsidiaries
in general. Likewise, the words “we”, “us” and “our” are also used to
refer to subsidiaries in general or to those who work for them. These
expressions are also used where no useful purpose is served by
identifying the particular company or companies.

Forward-Looking Statements
This press release and any
materials distributed in connection with this press release may contain
forward-looking statements, beliefs or opinions regarding Takeda’s
future business, future position and results of operations, including
estimates, forecasts, targets and plans for Takeda. In particular, this
press release contains forecasts and management estimates related to the
financial and operational performance of Takeda, including statements
regarding forecasts for Revenue, Operating profit, Adjusted EBITDA,
Profit before income taxes, Net profit attributable to owners of Takeda,
Basic earnings per share, Amortization and impairment and other
income/expense, Underlying Revenue, Underlying Core Earnings margin,
Underlying Core EPS and Net Debt. Without limitation, forward looking
statements often include the words such as “targets”, “plans”,
“believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “will”,
“may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects”
or words or terms of similar substance or the negative thereof. Any
forward-looking statements in this document are based on the current
assumptions and beliefs of Takeda in light of the information currently
available to it. Such forward-looking statements do not represent any
guarantee by Takeda or its management of future performance and involve
known and unknown risks, uncertainties and other factors, including but
not limited to: the economic circumstances surrounding Takeda’s
business, including general economic conditions in Japan, the United
States and worldwide; competitive pressures and developments; applicable
laws and regulations; the success of or failure of product development
programs; decisions of regulatory authorities and the timing thereof;
changes in exchange rates; claims or concerns regarding the safety or
efficacy of marketed products or products candidates; and post-merger
integration with acquired companies, any of which may cause Takeda’s
actual results, performance, achievements or financial position to be
materially different from any future results, performance, achievements
or financial position expressed or implied by such forward-looking
statements. For more information on these and other factors which may
affect Takeda’s results, performance, achievements, or financial
position, see “Item 3. Key Information—D. Risk Factors” in Takeda’s
Registration Statement on Form 20-F filed with the U.S. Securities and
Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/
or at www.sec.gov.
Neither Takeda nor its management gives any assurances that the
expectations expressed in these forward-looking statements will turn out
to be correct, and actual results, performance or achievements could
materially differ from expectations. Persons receiving this press
release should not place undue reliance on forward looking statements.
Takeda undertakes no obligation to update any of the forward-looking
statements contained in this press release or any other forward-looking
statements it may make. Past performance is not an indicator of future
results and the results of Takeda in this press release may not be
indicative of, and are not an estimate, forecast or projection of
Takeda’s future results.

Contacts

Japanese Media
Kazumi Kobayashi
[email protected]
+81
(0) 3-3278-2095

Media outside Japan
Sara Noonan
[email protected]
+1-617-551-3683